Carnegie Mellon University

Ricardo Dolmetsch

Global Head of Neuroscience at the Novartis Institute for Biomedical Research 

May 22, 2014

Rashid Auditorium, Carnegie Mellon University

Insights Into the Brain of a Child With Autism

Press Release

2014-dolmetsch.jpg

Dolmetsch’s research is highly innovative and he has staked out pioneering terrain to help us understand the biochemistry of autism,” said Marlene Behrmann, CNBC co-director and the George A. and Helen Dunham Cowan Professor of Cognitive Neuroscience at CMU. “In particular, he has begun to identify gene mutations associated with the neurodevelopmental diseases and, furthermore, has gone beyond this to shed light on what the effect of the mutations are on the nervous system. The goal of his work ultimately is to alter the molecular biology of the brain cells to make them function more normally and this is a very exciting research program. We are happy to recognize his accomplishments and to award the Carnegie Prize to Dr. Dolmetsch.”

At Novartis, Dolmetsch leads the group responsible for leveraging advances in human genetics to model and treat neuropsychiatric and neurodegenerative diseases. Focal areas include genomics, induced pluripotent stem cells and brain circuitry.

Artwork

Each year, the Andrew Carnegie winner receives an original piece of artwork commissioned from artist Greg Dunn.

Neural Nebulae

Greg Dunn artwork

carnegiecorporationlogo.png